EcoDrugPlus

Mitogen-Activated Protein Kinase 8

Ensembl ID : ENSUMAG00000015606
Gene Symbol: MAPK8
4 Cross references
294 Possible Orthologues:

Mitogen-Activated Protein Kinase 9

Ensembl ID : ENSUMAG00000024571
Gene Symbol: MAPK9
4 Cross references
219 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSUMAG00000012208
Gene Symbol: MAP2K1
4 Cross references
201 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 2

Ensembl ID : ENSUMAG00000007513
Gene Symbol: MAP2K2
3 Cross references
269 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 1

Ensembl ID : ENSUMAG00000009059
Gene Symbol: MAP3K1
4 Cross references
160 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 12

Ensembl ID : ENSUMAG00000010453
Gene Symbol: MAP3K12
4 Cross references
254 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSUMAG00000005040
Gene Symbol: MAP3K13
4 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 5

Ensembl ID : ENSUMAG00000023881
Gene Symbol: MAP3K5
4 Cross references
203 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 8

Ensembl ID : ENSUMAG00000015900
Gene Symbol: MAP3K8
4 Cross references
198 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 9

Ensembl ID : ENSUMAG00000009583
Gene Symbol: MAP3K9
4 Cross references
194 Possible Orthologues:

Monoamine Oxidase A

Ensembl ID : ENSUMAG00000013857
Gene Symbol: MAOA
4 Cross references
146 Possible Orthologues:

Monoamine Oxidase B

Ensembl ID : ENSUMAG00000013852
Gene Symbol: MAOB
4 Cross references
330 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).